MedTrace Logo

Selegiline and Reward Processing

NCT04130087 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-10-17

No results posted yet for this study

Summary

There has been growing interest in the relationship between reward processing and clinical symptoms of depression such as anhedonia (loss of interest and response to pleasurable activities).

The aim of the study is to investigate the acute effects of a single dose of selegiline (an irreversible monoamine oxidase B inhibitor) on reward and emotional processing in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Selegiline Hydrochloride 10 MG

Single 10mg tablet of Selegiline Hydrochloride

DRUG

Placebo

Single Placebo Tablet, identical appearance to experimental tablet.

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Catherine Harmer, PhD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-18
Primary Completion
2020-09-10
Completion
2020-09-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04130087 on ClinicalTrials.gov